These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2162062)

  • 1. Double-blind study of true vs. sham plasmapheresis in patients being treated with immunosuppression for acute attacks of multiple sclerosis.
    Weiner HL; Dau PC; Khatri BO; Petajan J; Birnbaum G; McQuillen MP; Fosburg MT; Feldstein M; Orav J
    Prog Clin Biol Res; 1990; 337():283. PubMed ID: 2162062
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current therapy of multiple sclerosis. Are there indications for plasmapheresis?].
    Schönbeck S; Hohlfeld R
    Nervenarzt; 1992 Feb; 63(2):116-9. PubMed ID: 1314334
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis.
    Hauser SL; Fosburg M; Kevy S; Weiner HL
    Prog Clin Biol Res; 1982; 106():239-54. PubMed ID: 6184727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis.
    Weiner HL; Dau PC; Khatri BO; Petajan JH; Birnbaum G; McQuillen MP; Fosburg MT; Feldstein M; Orav EJ
    Neurology; 1989 Sep; 39(9):1143-9. PubMed ID: 2549450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunosuppressive treatment im multiple sclerosis].
    Mertin J
    Fortschr Med; 1980 Oct; 98(37):1431-6. PubMed ID: 6253370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years].
    Trouillas P; Neuschwander P; Nighoghossian N; Adeleine P; Tremisi P
    Rev Neurol (Paris); 1989; 145(5):369-77. PubMed ID: 2662340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
    Dawson DM; Carter JL; Hafler DA; Weiner HL
    Riv Neurol; 1987; 57(2):88-91. PubMed ID: 3039645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoadsorption (IA) versus plasma exchange (PE) in multiple sclerosis--first results of a double blind controlled trial.
    Schmitt E; Behm E; Buddenhagen F; Ernst B; Hitzschke B; Kracht M; Korten G; Kundt G; Meyer-Rienecker H; Osten B
    Prog Clin Biol Res; 1990; 337():289-92. PubMed ID: 2191322
    [No Abstract]   [Full Text] [Related]  

  • 9. Azathioprine in multiple sclerosis: the cons.
    Silberberg DH
    Neurology; 1988 Jul; 38(7 Suppl 2):24-7. PubMed ID: 3290710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis. II. A critical assessment of immunotherapy.
    Durelli L; Bergamini L
    Riv Neurol; 1989; 59(5):191-201. PubMed ID: 2483962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
    Carter JL; Hafler DA; Dawson DM; Orav J; Weiner HL
    Neurology; 1988 Jul; 38(7 Suppl 2):9-14. PubMed ID: 2838768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive drug therapy with plasmapheresis in chronic progressive multiple sclerosis: a controlled study.
    Khatri BO; Harrington GJ; Schmoll D; McQuillen MP
    J Clin Apher; 1984; 2(1):135-7. PubMed ID: 6536654
    [No Abstract]   [Full Text] [Related]  

  • 14. [New therapeutic possibilities for disseminated sclerosis?].
    Wanscher B; Sørensen PS
    Ugeskr Laeger; 1994 Oct; 156(43):6353-8. PubMed ID: 7810008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current therapy of multiple sclerosis].
    Vass K; Schmied M
    Wien Med Wochenschr; 1996; 146(19-20):514-9. PubMed ID: 9082651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
    Polman CH; Dahlke F; Thompson AJ; Ghazi M; Kappos L; Miltenburger C; Pozilli C
    Mult Scler; 1995; 1 Suppl 1():S51-4. PubMed ID: 9345400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive immunosuppression in multiple sclerosis.
    Zaffaroni M; Ghezzi A; Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S13-7. PubMed ID: 16708175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of multiple sclerosis.
    McFarlin DE
    N Engl J Med; 1983 Jan; 308(4):215-7. PubMed ID: 6294519
    [No Abstract]   [Full Text] [Related]  

  • 19. Current medical treatment of multiple sclerosis.
    Alter M
    Clin Ther; 1983; 5(5):455-60. PubMed ID: 6193881
    [No Abstract]   [Full Text] [Related]  

  • 20. Experience with cyclophosphamide in multiple sclerosis: the cons.
    Likosky WH
    Neurology; 1988 Jul; 38(7 Suppl 2):14-8. PubMed ID: 3290708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.